MA34229B1 - Compositions et méthodes de modulation des kinases et leurs indications - Google Patents

Compositions et méthodes de modulation des kinases et leurs indications

Info

Publication number
MA34229B1
MA34229B1 MA35365A MA35365A MA34229B1 MA 34229 B1 MA34229 B1 MA 34229B1 MA 35365 A MA35365 A MA 35365A MA 35365 A MA35365 A MA 35365A MA 34229 B1 MA34229 B1 MA 34229B1
Authority
MA
Morocco
Prior art keywords
disease
cancer
trkb
flt3
fms
Prior art date
Application number
MA35365A
Other languages
English (en)
Inventor
Jiazhong Zhang
Prabha N Ibrahim
Wayne Spevak
James Tsai
Todd Ewing
Ying Zhang
Chao Zhang
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44816304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34229(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of MA34229B1 publication Critical patent/MA34229B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés et leurs sels, leurs conjugués, leurs dérivés, leurs formes, des formulations en contenant et leurs utilisations. Selon certains aspects et modes de réalisation, les composés décrits ou leurs sels, leurs conjugués, leurs dérivés, leurs formes, les formulations en contenant sont actifs sur une ou plusieurs des protéines kinases Fms, Kit, Flt3, TrkA, TrkB et TrkC. L'invention concerne également des méthodes d'utilisation de ces substances à des fins de traitement de maladies et d'affections, dont des maladies et affections associées à l'activité d'une ou plusieurs des protéines kinases Fms, Kit, Flt3, TrkA, TrkB et TrkC, cela comprenant la polyarthrite, l'arthrose, l'ostéoporose, l'ostéolyse périprothétique, la sclérodermie généralisée, les troubles de la démyélinisation, la sclérose en plaques, la maladie de Charcot-Marie-Tooth, la sclérose latérale amyotrophique, la maladie d'Alzheimer, la maladie de Parkinson, l'ischémie globale, la colite ulcéreuse, la maladie de Crohn, le purpura thrombocytopénique d'origine immunitaire, l'athérosclérose, le lupus érythémateux disséminé, la myélopréparation pour greffe autologue, le rejet de greffe, la glomérulonéphrite, la néphrite interstitielle, la néphropathie lupique, la nécrose tubulaire, la néphropathie diabétique, l'hypertrophie rénale, le diabète de type I, la douleur aiguë, la douleur inflammatoire, la douleur neuropathique, la leucémie myéloïde aiguë, le mélanome, le myélome multiple, le cancer du sein, le cancer de la prostate, le cancer du pancréas, le cancer du poumon, le cancer de l'ovaire, les gliomes, le glioblastome, la neurofibromatose, les métastases osseuses ostéolytiques, les métastases cérébrales, les tumeurs stromales gastro-intestinales et les tumeurs à cellules géantes.
MA35365A 2010-04-21 2011-04-20 Compositions et méthodes de modulation des kinases et leurs indications MA34229B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32662610P 2010-04-21 2010-04-21
PCT/US2011/033192 WO2011133637A2 (fr) 2010-04-21 2011-04-20 Compositions et méthodes de modulation des kinases et leurs indications

Publications (1)

Publication Number Publication Date
MA34229B1 true MA34229B1 (fr) 2013-05-02

Family

ID=44816304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35365A MA34229B1 (fr) 2010-04-21 2011-04-20 Compositions et méthodes de modulation des kinases et leurs indications

Country Status (37)

Country Link
US (3) US8901118B2 (fr)
EP (1) EP2560972B1 (fr)
JP (2) JP5808793B2 (fr)
KR (1) KR101799126B1 (fr)
CN (1) CN102947305B (fr)
AR (2) AR080940A1 (fr)
AU (1) AU2011242778B2 (fr)
BR (1) BR112012026927A2 (fr)
CA (1) CA2796998C (fr)
CL (1) CL2012002937A1 (fr)
CO (1) CO6620045A2 (fr)
CR (1) CR20120536A (fr)
CY (1) CY1120554T1 (fr)
DK (1) DK2560972T3 (fr)
EA (1) EA028105B1 (fr)
EC (1) ECSP12012245A (fr)
ES (1) ES2641643T3 (fr)
GE (1) GEP20156251B (fr)
HR (1) HRP20171660T1 (fr)
HU (1) HUE036461T2 (fr)
IL (1) IL222498A (fr)
LT (1) LT2560972T (fr)
MA (1) MA34229B1 (fr)
MX (1) MX336056B (fr)
MY (1) MY160780A (fr)
NZ (2) NZ603087A (fr)
PE (1) PE20130240A1 (fr)
PL (1) PL2560972T3 (fr)
PT (1) PT2560972T (fr)
RS (1) RS56588B1 (fr)
SG (2) SG10201505606QA (fr)
SI (1) SI2560972T1 (fr)
TW (2) TWI619713B (fr)
UA (1) UA109128C2 (fr)
UY (1) UY33346A (fr)
WO (1) WO2011133637A2 (fr)
ZA (1) ZA201207898B (fr)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RS53350B (en) 2008-09-22 2014-10-31 Array Biopharma, Inc. SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
KR101634833B1 (ko) 2008-10-22 2016-06-29 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
JP2013511541A (ja) 2009-11-18 2013-04-04 プレキシコン インコーポレーテッド キナーゼ調節のための化合物および方法、ならびにその適応
CA2784393A1 (fr) 2009-12-23 2011-06-30 Plexxikon, Inc. Composes et methodes pour la modulation des kinases, et leurs indications
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EP2918588B1 (fr) 2010-05-20 2017-05-03 Array Biopharma, Inc. Composés macrocycliques comme inhibiteurs de la kinase TRK
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MA35024B1 (fr) 2011-04-05 2014-04-03 Pfizer Ltd Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014018888A1 (fr) 2012-07-26 2014-01-30 Confluence Life Sciences Inc. Composés 4-alcoxy/aralcoxy-5-substitués-pyrrolopyrimidine en tant qu'inhibiteurs de tak1 dans le traitement d'une maladie
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ トロポミオシン関連キナーゼ阻害剤
WO2014053968A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20151997A1 (es) 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
EP3628749A1 (fr) 2013-07-30 2020-04-01 Blueprint Medicines Corporation Fusions de ntrk2
CA2934010A1 (fr) 2013-12-20 2015-06-25 Pfizer Limited Inhibiteurs de kinase apparentes a la n-acylpiperidine ether tropomyosine
CN114736305B (zh) * 2014-01-10 2023-05-05 比奥贝拉蒂治疗公司 因子viii嵌合蛋白及其用途
WO2015134536A1 (fr) 2014-03-04 2015-09-11 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications
WO2015159175A1 (fr) 2014-04-15 2015-10-22 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine contenant à la fois un 1h-pyrazole et un fragment pyrimidine
EP3140298A1 (fr) 2014-05-07 2017-03-15 Pfizer Inc. Inhibiteurs de kinases apparentées à la tropomyosine
WO2016009296A1 (fr) 2014-07-16 2016-01-21 Pfizer Inc. Inhibiteurs de kinase liés à la n-acylpipéridine éther tropomyosine
WO2016020784A1 (fr) 2014-08-05 2016-02-11 Pfizer Inc. Inhibiteurs de kinases apparentées à la n-acylpyrrolidine éther tropomyosine
AU2015318233B2 (en) 2014-09-15 2020-03-12 Plexxikon Inc. Heterocyclic compounds and uses thereof
DK3699181T3 (da) 2014-11-16 2023-03-20 Array Biopharma Inc Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat
WO2016100963A1 (fr) * 2014-12-19 2016-06-23 Research Institute At Nationwide Children's Hospital Composés de pyruvate pour le traitement de la neuropathie périphérique
US9695200B2 (en) 2015-01-23 2017-07-04 Confluence Life Sciences, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN112574196A (zh) 2015-05-06 2021-03-30 普莱希科公司 调节激酶的1H-吡咯并[2,3-b]吡啶衍生物的合成
SI3292123T1 (sl) 2015-05-06 2020-10-30 Plexxikon Inc. Trdne oblike spojine, ki modulira kinaze
CN107771178B (zh) 2015-05-22 2021-04-06 普莱希科公司 杂环化合物的合成
CA2988423A1 (fr) 2015-06-01 2016-12-08 Loxo Oncology, Inc. Methodes de diagnostic et de traitement du cancer
PT3322706T (pt) 2015-07-16 2021-03-08 Array Biopharma Inc Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MY195977A (en) 2015-09-21 2023-02-27 Plexxikon Inc Heterocyclic Compounds and uses Thereof
BR112018008357A2 (pt) 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
KR20180086247A (ko) 2015-12-07 2018-07-30 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법과 이들에 대한 징후
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
AU2017232610B2 (en) 2016-03-16 2021-07-22 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
RU2751767C2 (ru) 2016-04-04 2021-07-16 Локсо Онколоджи, Инк. Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида
TN2019000332A1 (en) 2016-04-04 2021-05-07 Loxo Oncology Inc Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
SG11201809931YA (en) * 2016-05-11 2018-12-28 Beta Pharma Inc 2-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancers
LT3458456T (lt) 2016-05-18 2021-02-25 Loxo Oncology, Inc. (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas
JP2019530650A (ja) 2016-08-24 2019-10-24 アークル インコーポレイテッド アミノ−ピロロピリミジノン化合物およびその使用方法
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20180153922A1 (en) 2016-12-06 2018-06-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
AU2017395023B2 (en) 2016-12-23 2022-04-07 Plexxikon Inc. Compounds and methods for CDK8 modulation and indications therefor
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
JP2020511467A (ja) 2017-03-20 2020-04-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ブロモドメインを阻害する４−（１−（１，１−ジ（ピリジン−２−イル）エチル）−６−（３，５−ジメチルイソオキサゾール−４−イル）−１Ｈ−ピロロ［３，２−ｂ］ピリジン−３−イル）安息香酸の結晶形
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
TWI805599B (zh) 2017-07-25 2023-06-21 美商第一三共公司 激酶調節化合物之調配物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3079029A1 (fr) 2017-10-13 2019-04-18 Plexxikon Inc. Formes solides d'un compose pour la modulation de kinases
WO2019084285A1 (fr) 2017-10-26 2019-05-02 Qian Zhao Formulations d'un inhibiteur de kinase trk macrocyclique
BR112020007972A2 (pt) 2017-10-27 2020-10-20 Plexxikon, Inc. formulações de composto que modula quinases
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
JP7060694B2 (ja) 2018-01-18 2022-04-26 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
CN112119072A (zh) 2018-03-20 2020-12-22 普莱希科公司 用于ido和tdo调节的化合物和方法，以及其适应症
EP3773725A1 (fr) 2018-03-29 2021-02-17 Loxo Oncology Inc. Traitement de cancers associés à trk
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
KR102612513B1 (ko) 2018-07-31 2023-12-12 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
CN110833552A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途
CN110833557A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肾小管肾炎的用途
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
US20220081438A1 (en) 2018-12-19 2022-03-17 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN113474337A (zh) 2018-12-19 2021-10-01 奥瑞生物药品公司 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物
KR20220018475A (ko) 2019-04-09 2022-02-15 플렉시콘 인코퍼레이티드 Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
JP2023522949A (ja) 2020-04-23 2023-06-01 オプナ バイオ ソシエテ アノニム Ｃｄ７３調節のための化合物及び方法並びにそれらの表示
MX2023002037A (es) 2020-08-18 2023-06-12 Incyte Corp Proceso e intermediarios para preparar un inhibidor de las cinasas de janus (jak).
WO2022040172A1 (fr) 2020-08-18 2022-02-24 Incyte Corporation Procédé et intermédiaires pour la préparation d'un inhibiteur de jak1
EP4199926A1 (fr) 2020-08-21 2023-06-28 Plexxikon Inc. Thérapies anticancéreuses à base de médicaments combinatoires
CN114920744B (zh) * 2021-11-16 2024-05-07 中国药科大学 一种非共价btk激酶抑制剂及其生物用途
WO2023179793A1 (fr) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 Forme cristalline d'un composé 1h-pyrrolo[2,3-c]pyridine et son procédé de préparation

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
YU83302A (sh) * 2000-06-26 2005-09-19 Pfizer Products Inc. Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
GB0107368D0 (en) * 2001-03-23 2001-05-16 Novartis Ag Organic compounds
MXPA03010269A (es) 2001-05-11 2004-05-05 Vertex Pharma Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US20040171062A1 (en) 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
EP1558751A4 (fr) 2002-09-16 2007-08-22 Plexxikon Inc Structure cristalline de la proteine kinase pim-1
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US20050048573A1 (en) 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
SE0300456D0 (sv) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1627045A2 (fr) 2003-02-28 2006-02-22 Plexxikon, Inc. Structure cristalline de pyk2 et ses utilisations
US20050079548A1 (en) 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
NZ544609A (en) 2003-07-11 2008-07-31 Warner Lambert Co Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
JP4845730B2 (ja) 2003-07-17 2011-12-28 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
WO2005028624A2 (fr) 2003-09-15 2005-03-31 Plexxikon, Inc. Echafaudages moleculaires pour le developpement de ligands des proteines kinases
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
US7517970B2 (en) 2003-12-19 2009-04-14 Plexxikon, Inc. Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same
PL1713806T3 (pl) * 2004-02-14 2013-09-30 Irm Llc Związki i kompozycje jako inhibitory kinaz białkowych
US8507484B2 (en) * 2004-02-26 2013-08-13 Kyowa Hakko Kirin Co., Ltd. Preventive and/or therapeutic agent for neutrophilic inflammatory diseases
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
BRPI0511512A (pt) * 2004-05-27 2007-12-26 Pfizer Prod Inc derivados pirrolpirimidina úteis no tratamento do cáncer
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
JP2008503473A (ja) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
JP2008512380A (ja) 2004-09-03 2008-04-24 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤
AU2005311826A1 (en) 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
US7531568B2 (en) 2004-11-30 2009-05-12 Plexxikon, Inc. PPAR active compounds
US20060160135A1 (en) 2004-12-08 2006-07-20 Weiru Wang SF-1 and LRH-1 modulator development
CN101223169A (zh) * 2005-05-17 2008-07-16 普莱希科公司 吡咯并[2,3-b]吡啶衍生物蛋白激酶抑制剂
WO2007013896A2 (fr) 2005-05-17 2007-02-01 Plexxikon, Inc. Composes modulant l'activite de c-kit et c-fms et utilisations
DK1893612T3 (da) 2005-06-22 2011-11-21 Plexxikon Inc Pyrrol [2,3-B]pyridin-derivater som proteinkinasehæmmere
US20080234349A1 (en) 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
TW200800872A (en) 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
US20070072904A1 (en) 2005-09-07 2007-03-29 Jack Lin PPAR active compounds
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US8093246B2 (en) 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
AU2007336811A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
EP2121591A2 (fr) 2007-03-08 2009-11-25 Plexxikon, Inc. Composés actifs sur ppar
CA2686379A1 (fr) * 2007-05-04 2008-11-13 Irm Llc Derives de phenylaminopyrimidine et compositions renfermant ces derives en tant qu'inhibiteurs de c-kit et de pdgfr kinase
WO2009012283A1 (fr) 2007-07-17 2009-01-22 Plexxikon Inc. Composés et procédés pour la modulation des kinases et leurs indications
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
BRPI0908849A2 (pt) * 2008-02-22 2015-08-25 Irm Llc Composto e composições como c-kit e inibidores de pdgfr quinase
WO2009115084A2 (fr) 2008-03-20 2009-09-24 Schebo Biotech Ag Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
PE20091846A1 (es) 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8158636B2 (en) 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009152087A1 (fr) 2008-06-10 2009-12-17 Plexxikon, Inc. Composés hétéroaryles bicycliques et procédés destinés à la modulation de kinases, et des indications pour celle-ci
JP5767965B2 (ja) 2008-06-10 2015-08-26 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節する５ｈ−ピロロ［２，３−ｂ］ピラジン誘導体、およびその適応症
PT2384326E (pt) 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
KR101634833B1 (ko) 2008-10-22 2016-06-29 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
KR20110130463A (ko) 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
WO2010104945A1 (fr) 2009-03-11 2010-09-16 Plexxikon, Inc. Dérivés de pyrrolo [2, 3-b] pyridine pour l'inhibition des kinases raf
WO2010111527A1 (fr) 2009-03-26 2010-09-30 Plexxikon, Inc. Pyrazolo [ 3, 4 -b] pyridines en tant qu'inhibiteurs de la kinase et leur utilisation médicale
ES2552386T3 (es) 2009-04-03 2015-11-27 F. Hoffmann-La Roche Ag Composiciones de {3-[5-(4-cloro-fenil)-1H-pirrol[2,3-b]piridin-3-carbonil]-2,4-difluoro-fenil}-amida del ácido propano-1-sulfónico y usos de las mismas
SG175877A1 (en) 2009-05-04 2011-12-29 Plexxikon Inc Compounds and methods for inhibition of renin, and indications therefor
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
JP2013511541A (ja) 2009-11-18 2013-04-04 プレキシコン インコーポレーテッド キナーゼ調節のための化合物および方法、ならびにその適応
CA2784393A1 (fr) 2009-12-23 2011-06-30 Plexxikon, Inc. Composes et methodes pour la modulation des kinases, et leurs indications
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US8642606B2 (en) 2010-09-29 2014-02-04 Plexxikon Inc. ZAP-70 active compounds
AU2012214762B2 (en) 2011-02-07 2015-08-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2012255275B2 (en) 2011-05-17 2016-01-28 Plexxikon Inc. Kinase modulation and indications therefor
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
SG11201504754QA (en) 2012-12-21 2015-07-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
PE20151997A1 (es) 2013-03-15 2016-01-13 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
BR112015028845A2 (pt) 2013-05-30 2017-07-25 Plexxikon Inc compostos para a modulação da quinase e indicações da mesma
WO2015134536A1 (fr) 2014-03-04 2015-09-11 Plexxikon Inc. Composés et méthodes de modulation des kinases, et leurs indications

Also Published As

Publication number Publication date
UY33346A (es) 2011-10-31
EA201290973A1 (ru) 2013-04-30
PT2560972T (pt) 2017-10-09
RS56588B1 (sr) 2018-02-28
CN102947305A (zh) 2013-02-27
AR115233A2 (es) 2020-12-09
NZ603087A (en) 2015-01-30
DK2560972T3 (da) 2017-11-27
NZ703538A (en) 2016-11-25
EA028105B1 (ru) 2017-10-31
MX336056B (es) 2016-01-07
AR080940A1 (es) 2012-05-16
SI2560972T1 (sl) 2017-12-29
HUE036461T2 (hu) 2018-07-30
US8901118B2 (en) 2014-12-02
KR20130066621A (ko) 2013-06-20
PL2560972T3 (pl) 2018-01-31
UA109128C2 (ru) 2015-07-27
BR112012026927A2 (pt) 2017-10-10
TWI510487B (zh) 2015-12-01
HRP20171660T1 (hr) 2017-12-15
SG184874A1 (en) 2012-11-29
CN102947305B (zh) 2016-07-06
EP2560972B1 (fr) 2017-09-20
AU2011242778B2 (en) 2015-09-03
US9682981B2 (en) 2017-06-20
CA2796998C (fr) 2019-03-05
CL2012002937A1 (es) 2013-01-25
JP5808793B2 (ja) 2015-11-10
TW201544506A (zh) 2015-12-01
WO2011133637A3 (fr) 2012-02-09
JP2013525363A (ja) 2013-06-20
LT2560972T (lt) 2017-10-25
CA2796998A1 (fr) 2011-10-27
GEP20156251B (en) 2015-02-25
IL222498A (en) 2016-10-31
CR20120536A (es) 2013-02-01
TWI619713B (zh) 2018-04-01
TW201136929A (en) 2011-11-01
AU2011242778A1 (en) 2012-11-22
CO6620045A2 (es) 2013-02-15
ZA201207898B (en) 2016-09-28
US20150183793A1 (en) 2015-07-02
US20170283423A1 (en) 2017-10-05
JP2016028073A (ja) 2016-02-25
MX2012012197A (es) 2012-12-17
MY160780A (en) 2017-03-15
PE20130240A1 (es) 2013-03-04
US20110263595A1 (en) 2011-10-27
KR101799126B1 (ko) 2017-11-17
EP2560972A4 (fr) 2013-11-20
SG10201505606QA (en) 2015-08-28
WO2011133637A2 (fr) 2011-10-27
CY1120554T1 (el) 2019-07-10
ECSP12012245A (es) 2012-11-30
ES2641643T3 (es) 2017-11-10
EP2560972A2 (fr) 2013-02-27

Similar Documents

Publication Publication Date Title
MA34229B1 (fr) Compositions et méthodes de modulation des kinases et leurs indications
EA201290331A1 (ru) Модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
MX2010006046A (es) Moduladores de gamma secretasa.
EA201690391A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
NZ593096A (en) Carbazole carboxamide compounds useful as kinase inhibitors
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
WO2009143018A3 (fr) Composés et procédés de modulation des kinases, et indications associées
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
EA201100749A1 (ru) Производные пиридина и пиримидина в качестве ингибиторов фосфодиэстеразы 10
TW200738666A (en) Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
JO2910B1 (en) Organic compounds
EA200901142A1 (ru) 18f фторбензоильные меченые биологически активные соединения в качестве диагностических визуализирующих средств, а также бензотриазол-1-илоксибензоильные, 2,5-(диоксопирролидин-1-илокси)бензоильные и триметиламмониобензоильные предшественники
ATE513828T1 (de) Phenyl-ä3-ä3-(1h-pyrrol-2-yl)-ä1,2,4üoxadiazol- - ylüpiperidin-1-ylü-methanon-derivate und verwandte verbindungen als positive allosterische modulatoren metabotroper glutamatrezeptoren
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
MX2015014861A (es) Pirimidinas sustituidas con heterocicloalquilo c-enlazado y sus usos.
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA201290329A1 (ru) Селективные гетрероциклические модуляторы рецептора сфингозин-1-фосфата
TN2009000063A1 (en) Compounds and methods for 18f labeled agents
EA201100078A1 (ru) Производные пиримидина в качестве ингибиторов киназы
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
UA107336C2 (ru) Синтез и солевые формы (r)-5-((e)-2-пирролидин-3-илвинил) пиримидина
PE20090295A1 (es) Derivados de espirociclopropilpiperidina
EA200901030A1 (ru) Антагонист хроменового рецептора s1p1
TN2009000147A1 (en) Crystal modifications -3-(1h-indol-3-yl)-4-[2-(4-methyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrole-2,5-d ione